Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining therapies in development for Achondroplasia including vosoritide, TransCon CNP, TA-46, and Infigratinib (2 week delayed release to library)

Ticker(s): BMRN, ASND, BBIO, Therachon

Who's the expert?

Name: Dr Gary A. Bellus - MD | PhD

Institution: Geisinger Medical Center

  • Director, Clinical Genetics & Genomic Medicine, Geisinger Health System.
  • Very familiar with achondroplasia and has taken care of hundreds of patients with this condition over the past 20 years.  
  • Board-certified and fellowship-trained specialist in clinical genetics. His clinical interests include skeletal dysplasia and genetic skin disorders.

Interview Questions
Q1.

Please describe your clinical practice; roughly how many patients with Achondroplasia do you currently manage?

Added By: c_admin
Q2.

How familiar are you with each vosoritide, TransCon CNP, TA-46, and Infigratinib?

Added By: c_admin
Q3.

Have you referred any patients or had a conversation about referring a patient to one of those clinical trials?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.